Trader 📈 bio-hacker 🧬 and weight lifter 💪🏼 Disclosure: Opinions only, not investment advice. DYOR. High risk, High reward stocks.
🇺🇸
Joined November 2024
- Tweets1.4K
- Following279
- Followers151
- Likes7K
David retweeted
$LEXX looking better today - up 15% and still valued below cash. News due on several fronts.
David retweeted
$LEXX 🗣️
The CEO is referring to Lexaria’s intensifying efforts to secure licensing deals and partnerships with pharma firms for DehydraTECH. Stronger patents improve negotiating leverage and support more frequent partner discussions across GLP-1, CBD (hypertension/epilepsy), and other applications, aiming for commercial relationships and out-licensing revenue.
$LEXX 🗣️
The CEO is referring to Lexaria’s intensifying efforts to secure licensing deals and partnerships with pharma firms for DehydraTECH. Stronger patents improve negotiating leverage and support more frequent partner discussions across GLP-1, CBD (hypertension/epilepsy), and other applications, aiming for commercial relationships and out-licensing revenue.
$LEXX 👀 “strengthens, supports our ongoing and accelerating business development programs” 🔥
$LEXX Lexaria Celebrates its 70th Patent Award accessnewswire.com/newsroom/…
David retweeted
$LEXX 👀 “strengthens, supports our ongoing and accelerating business development programs” 🔥
$LEXX Lexaria Celebrates its 70th Patent Award accessnewswire.com/newsroom/…
GLP-1 boom in China, India, Brazil could create $22 billion market by 2035, J.P. Morgan says
economictimes.indiatimes.com…
David retweeted
$LEXX Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule accessnewswire.com/newsroom/…
David retweeted
$LEXX “This final group is expected to complete their dosing in mid-November, to be followed by completion of all laboratory sample analyses and reporting.”
$LEXX Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule accessnewswire.com/newsroom/…
$LEXX 👀
$lexx Second, both the Lexaria DHT-sema tablet and capsule test articles will be formulated with SNAC, which will be the first time these formulations will be evaluated over a multi-dose, multi-week time period in humans. The five-week dosing duration of the Study is expected to be long enough to reach so-called steady-state, which is when drug concentrations in the body reach a constant concentration. 👀👀🎯
David retweeted
$lexx Second, both the Lexaria DHT-sema tablet and capsule test articles will be formulated with SNAC, which will be the first time these formulations will be evaluated over a multi-dose, multi-week time period in humans. The five-week dosing duration of the Study is expected to be long enough to reach so-called steady-state, which is when drug concentrations in the body reach a constant concentration. 👀👀🎯
$LEXX “This final group is expected to complete their dosing in mid-November, to be followed by completion of all laboratory sample analyses and reporting.”
$LEXX Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule accessnewswire.com/newsroom/…
David retweeted
$LEXX LEXXW - Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule
David retweeted
Those of us who fight so hard and yell so loud against this shit know that it is a Trojan horse importing radical islamists who are committed to the destruction of the west.
Those of you staying silent or are scared of social ostracism - look what the alternative is.
